Medpace Holdings, Inc. (NASDAQ: MEDP) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $18.3B. The Maz Rating grades it against the other companies in its sector.
Medpace Holdings, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $653.94, Medpace Holdings, Inc. trades at 35.6x trailing earnings, 6.4x sales and 31.2x book value, with an EV/EBITDA of 27.6. Over the last twelve months it generated about $2.8B of revenue and $514M of net income. It runs a gross margin of 29.1%, an operating margin of 21.4% and a net margin of 18.2%. It shows return on equity of 99.8%, return on invested capital of 62.2% and a free cash flow yield of 3.6%. On the balance sheet: a debt-to-equity ratio of 0.25 and a current ratio of 0.83. Over the past 52 weeks the share price ranged from $373.00 to $693.97, with a beta of 1.12.
Medpace Holdings, Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 4 Buy and 15 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Medpace Holdings, Inc. (MEDP) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 4.01% / 30% · Interest income / Revenue 0.75% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 4.01% / 33% · Receivables / Mkt Cap (36m) 2.54% / 49% · Interest income / Revenue 0.75% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 4.01% / 33.33% · Receivables / Mkt Cap (24m) 2.54% / 33.33% · Interest income / Revenue 0.75% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 27.9% / 33.33% · Receivables / Avg Assets (4Q) 19.9% / 33.33% · Interest income / Revenue 0.75% / 5% | Pass |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 30.6% / 33.33% · (Cash+Recv) / Total Assets 50.1% / 33.33% · Interest income / Revenue 0.75% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Medpace Holdings, Inc. (MEDP) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. Medpace Holdings, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.75% of each dividend: Medpace Holdings, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.